New hope for asian lung cancer patients: targeted drug shows promise in phase 3 trial
NCT ID NCT02838420
First seen Nov 01, 2025 · Last updated Jun 17, 2026 · Updated 25 times
Summary
This study tested two oral drugs, alectinib and crizotinib, in 187 Asian patients with a specific type of advanced lung cancer (ALK-positive non-small cell lung cancer) who had not received prior treatment. The goal was to see which drug better delayed cancer growth. Patients took either alectinib or crizotinib twice daily. The results help doctors choose the best treatment for this condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAPLASTIC LYMPHOMA KINASE-POSITIVE NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Asan Medical Center
Seoul, 05505, South Korea
-
Beijing Cancer Hospital
Beijing, 100142, China
-
Beijing Chest Hospital
Beijing, 101149, China
-
Fudan University Shanghai Cancer Center
Shanghai, 200032, China
-
Guangdong General Hospital
Guangzhou, 510080, China
-
Harbin Medical University Cancer Hospital
Harbin, 150081, China
-
Jiangsu Cancer Hospital
Nanjing, 210009, China
-
Jilin Cancer Hospital
Changchun, 132013, China
-
Kangbuk Samsung Hospital
Seoul, 03181, South Korea
-
Rajavithi Hospital
Bangkok, 10400, Thailand
-
Ramathibodi Hospital
Bangkok, 10400, Thailand
-
Samsung Medical Center
Seoul, 06351, South Korea
-
Shanghai Pulmonary Hospital
Shanghai, 200433, China
-
Shanghai chest hospital
Shanghai, 200030, China
-
Songklanagarind Hospital
Songkhla, 90110, Thailand
-
Sun Yet-sen University Cancer Center
Guangzhou, 510060, China
-
The First Affiliated Hospital of College of Medicine, Zhejiang University
Hangzhou, 310003, China
-
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, 510120, China
-
West China Hospital, Sichuan University
Chengdu, 610041, China
-
Zhejiang Cancer Hospital
Hangzhou, 310022, China
-
the First Hospital of Jilin University
Changchun, 130021, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.